Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DOUGLAS GLENN YOUNG

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1346340296
CMS profile
61209
Location
SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$1,057.88

59 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $993.34 57
Education $64.54 2

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DOUGLAS GLENN YOUNG

NPI 1346340296 · CMS profile ID 61209

Allopathic & Osteopathic Physicians / Internal Medicine

SACRAMENTO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DOUGLAS GLENN YOUNG, NPI 1346340296, CMS profile ID 61209. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DOUGLAS GLENN YOUNG, NPI 1346340296, CMS profile ID 61209. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DOUGLAS GLENN YOUNG, NPI 1346340296, CMS profile ID 61209, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–59 of 59 matching records. This page contains 9 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1346340296?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

59 matching records · $1,057.88 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 59 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–59 of 59.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Lilly USA, LLC $22.2102/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 819067919 CMS
GlaxoSmithKline, LLC. $19.1902/09/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801640027 CMS
BOSTON SCIENTIFIC CORPORATION $17.4602/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 777755019 CMS
Biohaven Pharmaceuticals, Inc. $12.2102/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852661839 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $26.9902/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763471854 CMS
Merck Sharp & Dohme Corporation $19.8301/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 848591953 CMS
Biohaven Pharmaceuticals, Inc. $25.8001/20/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852661837 CMS
Amarin Pharma Inc. $13.8301/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815302029 CMS
GlaxoSmithKline, LLC. $22.3301/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 802934535 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,887.21 49
PY2020 $955.69 54
PY2021 $1,057.88 59
PY2022 $1,327.44 69
PY2023 $2,953.28 77
PY2024 $1,019.88 42
PY2025 $500.03 26

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $117.77 4
PY2025 Principal investigator $900,867.48 96
PY2024 Recipient $11,436.50 17
PY2024 Principal investigator $761,077.69 77
PY2023 Recipient $665.01 1
PY2023 Principal investigator $496,691.27 61
PY2022 Principal investigator $524,158.86 50
PY2021 Principal investigator $470,510.25 36
PY2020 Recipient $21.90 1
PY2020 Principal investigator $350,435.53 70
PY2019 Recipient $4,318.35 2
PY2019 Principal investigator $498,817.39 96

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

100 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Ionis Pharmaceuticals, Inc. $99.00 12/30/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246792198
Principal investigator 1 Ionis Pharmaceuticals, Inc. $400.00 12/30/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246792202
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,600.00 12/30/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246792206
Principal investigator 1 Ionis Pharmaceuticals, Inc. $4,500.00 12/30/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246792211
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,291.40 12/30/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184280704
Principal investigator 1 Verona Pharma, Inc. $16,359.90 12/19/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891549
Principal investigator 1 Verona Pharma, Inc. $29,307.71 12/17/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891547
Principal investigator 1 ModernaTX, Inc. $5,422.21 12/01/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964548
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,112.65 11/26/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184265539
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,112.65 11/20/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263301
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,075.10 11/14/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184260951
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 11/11/2025 Non-covered Recipient Entity
Northern California Research
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244047277
Principal investigator 1 Verona Pharma, Inc. $3,500.00 11/03/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891621
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,805.33 10/29/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253758
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35.98 10/28/2025 Non-covered Recipient Entity
Northern California Research
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244047275
Principal investigator 1 ModernaTX, Inc. $6,354.79 10/24/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964546
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,919.45 10/24/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253208
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,291.40 10/24/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184253210
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $31,139.39 10/16/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250829
Principal investigator 1 Ionis Pharmaceuticals, Inc. $575.00 10/14/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789132
Principal investigator 1 Ionis Pharmaceuticals, Inc. $1,500.00 10/14/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789136
Principal investigator 1 Ionis Pharmaceuticals, Inc. $2,040.00 10/14/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789141
Principal investigator 1 Ionis Pharmaceuticals, Inc. $19,684.28 10/14/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
IS354CS9 No dispute reported 06/30/2026 1246789145
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,150.46 10/08/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184247298
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,239.18 10/01/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184244469
Principal investigator 1 Janssen Research & Development, LLC $53,208.00 09/25/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167623
Principal investigator 1 ModernaTX, Inc. $2,901.01 09/24/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964536
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,848.99 09/24/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184242469
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,364.33 09/18/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184240670
Principal investigator 1 Verona Pharma, Inc. $7,747.59 09/17/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891441
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68,770.45 09/11/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184236081
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,557.92 09/03/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235027
Principal investigator 1 ModernaTX, Inc. $2,527.81 08/27/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964542
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,375.16 08/21/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184229793
Principal investigator 1 Verona Pharma, Inc. $9,000.00 08/15/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891505
Principal investigator 1 Verona Pharma, Inc. $1,800.00 08/15/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891507
Principal investigator 1 Verona Pharma, Inc. $1,000.00 08/15/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD No dispute reported 06/30/2026 1232891509
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,343.79 08/07/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184226295
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,857.55 07/31/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184222948
Principal investigator 1 Janssen Research & Development, LLC $4,622.00 07/28/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167581
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $3,415.00 07/25/2025 Non-covered Recipient Entity
Northern California Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248067003
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,821.28 07/23/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218031
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $48,093.75 07/23/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218033
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $27,410.40 07/23/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184218035
Principal investigator 1 ModernaTX, Inc. $4,690.37 07/18/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964544
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,252.62 07/10/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214510
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,856.42 07/03/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184212645
Principal investigator 1 ModernaTX, Inc. $6,534.34 06/25/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964538
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,856.42 06/25/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184210970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,126.31 06/11/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184205881
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,085.00 06/11/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184205883
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,333.45 06/11/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184205885
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,044.80 06/04/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204051
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,836.98 05/26/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184198481
Principal investigator 1 ModernaTX, Inc. $2,795.11 05/23/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964556
Principal investigator 1 Janssen Research & Development, LLC $6,091.00 05/20/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167558
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,761.07 05/19/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184196315
Principal investigator 1 ABBVIE INC. $11,404.00 05/15/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain No dispute reported 06/30/2026 1202484947
Principal investigator 1 Mylan Inc. $17,629.00 05/15/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
MR-100A-01-TD-3001-A PHASE 3, MULTICENTER, OPEN-LABEL, SINGLE ARM STUDY OF MR-100A-01 IN WOMEN OF CHILDBEARING POTENTIAL TO EVALUATE CONTRACEPTIVE EFFICACY AND SAFETY No dispute reported 06/30/2026 1238884865
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,036.80 05/12/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194251
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,088.90 05/12/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194253
Principal investigator 1 Lexicon Pharmaceuticals, Inc. $26,488.00 05/07/2025 Non-covered Recipient Entity
Northern California Research
LX9211.1-204-DPN No dispute reported 06/30/2026 1248066387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,619.10 05/05/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184192747
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $179.90 04/29/2025 Non-covered Recipient Entity
Northern California Research
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244047273
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $11,312.87 04/28/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190645
Principal investigator 1 ModernaTX, Inc. $4,251.62 04/25/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964552
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $24.55 04/22/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045456
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $85.56 04/22/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045458
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $45.00 04/22/2025 Non-covered Recipient Individual A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244045460
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,973.63 04/21/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184185249
Principal investigator 1 Janssen Research & Development, LLC $28,866.00 04/17/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167596
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,287.58 04/15/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183246
Recipient Teva Pharmaceuticals USA, Inc. $60.00 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046480
Recipient Teva Pharmaceuticals USA, Inc. $18.30 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046482
Recipient Teva Pharmaceuticals USA, Inc. $17.07 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046484
Recipient Teva Pharmaceuticals USA, Inc. $22.40 04/11/2025 Covered Recipient Physician A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma No dispute reported 06/30/2026 1244046486
Principal investigator 1 Janssen Research & Development, LLC $11,543.00 04/09/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167665
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,428.42 04/07/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184181904
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,497.88 04/01/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180590
Principal investigator 1 ModernaTX, Inc. $4,351.52 03/26/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964554
Principal investigator 1 Janssen Research & Development, LLC $7,516.00 03/25/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167675
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,320.54 03/19/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174434
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,467.23 03/11/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170776
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,146.69 03/04/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156638
Principal investigator 1 ModernaTX, Inc. $4,351.52 02/26/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964540
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,028.72 02/25/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184155488
Principal investigator 1 Janssen Research & Development, LLC $8,437.00 02/19/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167566
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,167.45 02/18/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154362
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,174.63 02/11/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184153040
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,174.63 02/05/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152508
Principal investigator 1 Eli Lilly and Company $22,155.00 01/28/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH CORPORATION
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187886064
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,992.27 01/28/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149806
Principal investigator 1 ModernaTX, Inc. $7,805.30 01/24/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1252964550
Principal investigator 1 Janssen Research & Development, LLC $1,811.00 01/21/2025 Non-covered Recipient Entity
Northern California Rsrch
A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years No dispute reported 06/30/2026 1175167600
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,997.24 01/21/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149148
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,990.06 01/14/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184147519
Principal investigator 1 Eli Lilly and Company $545.05 01/09/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH CORPORATION
A STUDY OF LY3556050 IN ADULT PARTICIPANTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN No dispute reported 06/30/2026 1187888028
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,023.27 01/07/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146018
Principal investigator 1 AstraZeneca Pharmaceuticals LP $58,813.74 01/03/2025 Non-covered Recipient Entity
NORTH COUNTY CLINICAL RESEARCH
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185540133
Principal investigator 1 Novartis Pharmaceuticals Corporation $10,356.03 01/01/2025 Non-covered Recipient Entity
NORTHERN CALIFORNIA RESEARCH
A 5-year, Randomized, Double-blind, Placebo-controlled, Multi-center Study Assessing the Efficacy, Safety, and Tolerability of Intra-articular Regimens of LNA043 Versus Placebo in Patients With Symptomatic Knee Osteoarthritis No dispute reported 06/30/2026 1190299117